CGAS — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL171247	0.51	8/20
SCHEMBL171248	0.51	8/20
SCHEMBL4845752	0.46	5/20
SCHEMBL4845761	0.46	5/20
SCHEMBL4401670	0.43	5/20
SCHEMBL4401676	0.43	5/20
SCHEMBL5461873	0.42	5/20
SCHEMBL5461877	0.42	5/20
SCHEMBL3402932	0.36	5/20
SCHEMBL3402936	0.36	5/20
SCHEMBL1645586	0.50	4/20
SCHEMBL4597661	0.52	3/20
SCHEMBL46579	0.51	3/20
SCHEMBL2510546	0.43	3/20
SCHEMBL3283475	0.35	3/20
Hydroxychloroquine (SCHEMBL4204503)	0.98	2/20
SCHEMBL4957066	0.88	2/20
Hydroxychloroquine (SCHEMBL4744123)	0.88	2/20
Chloroquine (SCHEMBL8933)	0.86	2/20
Chloroquine (SCHEMBL8934)	0.86	2/20

Clinical trials — most relevant to CGAS by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Switching of Sildenafil to Riociguat in CTEPH Patients	PHASE4	RECRUITING
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia	PHASE2/PHASE3	UNKNOWN
Chronic Sildenafil Treatment in Heart Failure	PHASE3	COMPLETED
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia	PHASE1/PHASE2	COMPLETED
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old	PHASE2	ACTIVE_NOT_RECRUITING
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction	PHASE2	COMPLETED
Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm	PHASE2	WITHDRAWN
The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment (CARAT)	PHASE2	COMPLETED
NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients	PHASE2	RECRUITING
Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals	PHASE1/PHASE2	COMPLETED
University of California, San Diego (UCSD) Suramin Autism Treatment-1 (SAT1) Trial	PHASE1/PHASE2	COMPLETED
Metformin's Effect on Glucagon-induced Glucose Production and Protein Metabolism.	PHASE1	COMPLETED
AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal Cancer	PHASE1	COMPLETED
Vitamin D Versus Sildenafil Citrate in Fetal Growth Restriction	PHASE1	COMPLETED
Uterine Artery Doppler Changes After Vaginal Administration of Isosorbide Mononitrate In Patients With URPL	EARLY_PHASE1	UNKNOWN
ADAR1 Expression Level in Rectal Cancer	nan	RECRUITING
Exploration of the Activity of DNA Located Outside of Cellular Nucleus to Amplify Inflammation in Inflammatory Bowel Disease in Children Through Biological Pathway Cyclic GMP-AMP Synthase (cGAS) - Stimulator of Interferon Genes (STING)	nan	COMPLETED
Ccf mtDNA as a Neurodegenerative Biomarker	nan	UNKNOWN
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside	nan	UNKNOWN
Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis	nan	NOT_YET_RECRUITING
Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still'S-like Diseases, and Other Undifferentiated Autoinflammatory Diseases)	nan	RECRUITING
A Dose-escalation Trial of Stereotactic Ablative Body Radiotherapy for Non-spine Bone & Lymph Node Oligometastates	nan	COMPLETED
Nicotinamide Levels in Serum, Aqueous Humor, and Tear Film in Glaucoma and Correlations With Mitochondrial Damage-Associated Molecular Patterns (mtDAMPs) and Senescence-Associated Secretory Phenotype (SASP)	nan	NOT_YET_RECRUITING
Mitigating Mitochondrial RNA Release During Aging to Control Inflammation and Senescence	nan	NOT_YET_RECRUITING
Effects of Pimecrolimus on Skin Biopsy Ex-plants From Patients With Atopic Dermatitis	nan	COMPLETED
Assessment of cfDNA-STING Axis as a Potential Pathological Marker in Atopic Dermatitis	nan	RECRUITING
Sildenafil Citrate Added to Low Molecular Weight Heparin and Low Dose Aspirin in High-risk Pregnancy	nan	WITHDRAWN
Intravenous Terbutaline in Severe Status Asthmaticus	nan	UNKNOWN
Arginine Metabolism in Youth With Type 2 Diabetes	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a CGAS binder may also engage these)

Protein	Name	Similarity
Q8C6L5	—	0.995	Q8C6L5 →
E1BGN7	—	0.995	E1BGN7 →
I3LM39	—	0.988	I3LM39 →
A0A913XCT1	—	0.987	A0A913XCT1 →
Q8BMD7	—	0.987	Q8BMD7 →
Q8TDB6	—	0.986	Q8TDB6 →
Q8BV79	—	0.983	Q8BV79 →
Q8CCG4	—	0.983	Q8CCG4 →
A1A4J7	—	0.983	A1A4J7 →
A0A482WD11	—	0.983	A0A482WD11 →
Q5TKR9	—	0.982	Q5TKR9 →
KAT6A	Histone acetyltransferase KAT6A	0.982	landscape →
P23497	—	0.981	P23497 →
Q60856	—	0.980	Q60856 →
A0A8B8BQ58	—	0.980	A0A8B8BQ58 →
RNF213	E3 ubiquitin-protein ligase RNF213	0.980	landscape →
Q92183	—	0.980	Q92183 →
Q6GQ81	—	0.979	Q6GQ81 →
A0A6J1SUS3	—	0.979	A0A6J1SUS3 →
A0A3M6TIF0	—	0.979	A0A3M6TIF0 →
Q91829	—	0.979	Q91829 →
B3NQ14	—	0.979	B3NQ14 →
G4YUT3	—	0.979	G4YUT3 →
Q8BWQ5	—	0.979	Q8BWQ5 →
Q1LVK9	—	0.979	Q1LVK9 →
A0A1W2PPD8	—	0.979	A0A1W2PPD8 →
Q29H56	—	0.979	Q29H56 →
Q13415	—	0.978	Q13415 →
Q5PQX1	—	0.978	Q5PQX1 →
P34088	—	0.978	P34088 →